Pharmacologic mechanisms of crystal meth

CMAJ. Canadian Medical Association Journal

Volumn 178, Issue 13, 2008, Pages 1679-1682

  Kish, Stephen J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; DEXAMPHETAMINE; DOPAMINE; METHAMPHETAMINE; NALOXONE; NALTREXONE; NORADRENALIN; SEROTONIN; SERTRALINE; VARENICLINE;

ATTENTION DEFICIT DISORDER; BRAIN DAMAGE; BRAIN DEPTH STIMULATION; BRAIN REGION; CANADA; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG EFFECT; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERANCE; HUMAN; LOW DRUG DOSE; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; OBESITY; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SYMPATHETIC NERVE; TOBACCO DEPENDENCE;

EID: 46049092642     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.071675     Document Type: Review

References (38)

1. Schifano F, Corkery JM, Cuffolo G. Smokable ("ice, "crystal meth") and nonsmokable amphetamine-type stimulants: clinical pharmacological and epidemiological issues, with special reference to the UK. Ann Ist Super Sanita 2007;43:110-5.
2. Degenhardt L, Roxburgh A, Black E, et al. The epidemiology of methamphetamine use and harm in Australia. Drug Alcohol Rev 2008;27:243-52.
3. Sulzer D, Sonders MS, Poulsen NW, et al. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 2005;75:406-33.
4. Center for Drug Evaluation and Research. Adderall XR Capsules. The US Food and Drug Administration. Available: www.fda.gov/cder/foi/label/2004/ 021303s005lbl.pdf (accessed 2008 May 7).
5. GlaxoSmithKline. Prescribing information: Dexedrine. Mississauga (ON): GlaxoSmithKline; 2007. Available: www.gsk.ca/english/docs-pdf/ Dexedrine_PM_EN_20070924.pdf (accessed 2008 May 7).
6. Martin WR, Sloan JW, Sapira JD, et al. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 1971;12:245-58.
7. Rothman RB, Baumann MH, Dersch CM, et al. Ampphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001;39:32-41.
8. Perez-Reyes M, White WR, McDonald SA, et al. Clinical effects of methamphetamine vapor inhalation. Life Sci 1991;49:953-9.
9. The Vaults of Erowid. Methamphetamine dosage. Grass valley (CA): Erowid; 2003. Available: www.erowid.org/chemicals/meth/meth_dose.shtml (accessed 2008 Apr 18).
10. Ovation Pharmaceuticals. Desoxyn product monograph. Available: www.ovation-pharma.com/pdfs/products/product_1.pdf (accessed 2008 Apr 30).
11. McGough JJ, Biderman J, Greenhill LL, et al. Pharmacokinetics of SLI381 (ADDER-ALL XR), an extended-release formulation of Adderall. J Am Acad Child Adolesc Psychiatry 2003;42:684-91.
12. Melega WP, Cho AK, Harvey D, et al. Methamphetamine blood concentrations in human abusers: Application to pharmacokinetic modeling. Synapse 2007;61:216-20.
13. Karch SB. Karchs Pathology of Drug Abuse. 3rd ed. Boca Raton (FL): CRC Press; 2001.
14. Rothman RB, Baumann MH. Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 2003;479:23-40.
15. Goldstein DS, Nurnberger J Jr, Simmons S, et al. Effects of injected sympathomimetic amines on plasma catecholamines and circulatory variables in man. Life Sci 1983;32:1057-63.
16. Michelson D, Allen AJ, Busner J, et al. Once-daily atonroxitene treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002;159:1896-901.
17. Roberts DC, Koob GF. Disruption of cocaine self-administration following 6-hydroxydopamine lesions of the ventral tegmental area in rats. Pharmacol Biochem Behav 1982;17:901-4.
18. Heimer L. A new anatomical framework for neuropsychiatrie disorders and drug abuse. Am J Psychiatry 2003;160:1726-39.
19. Gao G, Wang X, He S, et al. Clinical study for alleviating opiate drug psychological dependence by a method of ablating the nucleus accumbens with stereotactic surgery. Sterotact Funct Neurosurg 2003;81:96-104
20. Moszczynska A, Fitzmaurice P, Ang L, et al. Why is parkinsonism not a feature of human methamphetamine users? Brain 2004;127:363-70.
21. Dackis CA, Gold MA. New concepts in cocaine addiction: the dopamine depletion hypothesis. Neurosci Biobehav Rev 1985;9:469-77.
22. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988;85:5274-8.
23. Salamone JD, Correa M, Farra A, et al. Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits. Psychopharmacology (Berl) 2007;191:461-82.
24. Jayaram-Lindström NJ, Konstenius M, Eksborg S, et al. Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. Neuropsychopharmacology DOI: 10.1038/sj.npp.1301572. Epub 2007 Oct 24 ahead of print.
25. Kalivas PW. Neurobiology of cocaine addiction: implications for new pharmacotherapy. Am J Addict 2007;16:71-8.
26. Hyman SE. Addiction: a disease of learning and memory. Am J Psychiatry 2005;162:1414-22.
27. Kalivas PW, O'Brien C. Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology 2008;33:166-80.
28. Chang L, Alicata D, Ernst T, et al. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction 2007;102(Suppl 1):16-32.
29. Ricaurte GA, Seiden LS, Schuster CR. Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers. Brain Res 1984;303:359-64.
30. Ricaurte GA, Mechan AO, Yuan J, et al. Amphetamine treatment similar to that used in the treatment of adult attention-deficit/hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates. J Pharmacol Exp Ther 2005;315:91-8.
31. Rawson RA, Gonzales R, Brethen P. Treatment of methamphetamine use disorders: an update. J Subst Abuse Treat 2002;23:145-50.
32. Robinson TE, Kolb B. Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. J Neurosci 1997;17:8491-7.
33. Newton TF, Roache JD, De La Garza III R, et al. Buproprion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacol 2006;31:1537-44.
34. Rollema H, Coe JW, Chambers LK, et al. Rationale, pharmacology and clinical efficacy of partial agonists of α4β2 nACh receptors for smoking cessation. Trends Pharmacol Sci 2007;28:316-25.
35. Shearer J, Wodak A, Mattick RP, et al. Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence. Addiction 2001;96:1289-96
36. Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment-resistant depression. Neuron 2005;45:651-60.
37. Kuhn J, Lenartz D, Huff W, et al. Remission of alcohol dependency following deep brain stimulation of the nucleus accumbens: Valuable therapeutic implications? J Neurol Neurosurg Psychiat 2007;78:1152-3.
38. Shoptaw S, Huber A, Peck J, et al. Randomized placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend 2006;85:12-18.